Questions that our clients ask
- Would a regional funding approach to gain clinical experience be reasonable for PRODUCT X in RUS? How would this help expand local access?
- How can we provide access and support patients not covered under healthcare budget? How influential are third parties in reimbursement decisions (e.g. KOLs, patient associations
- What would be an appropriate price point for PRODUCT X for it to be successful in obtaining reimbursement listing?
- Would PRODUCT X have an advantage if it is manufactured / packaged domestically? What are opportunities for technology transfers to ensure a certain market share?
Local language capabilities
Specialized markets
The CBP difference
- We develop comprehensive knowledge of local market dynamics for stakeholders within key markets in Eastern Europe and the CIS region.
- We address nuanced questions on CEE-relates issues coming from regional and global clients on topics such as: IRP dynamics implications, interpretation of policy update and overview of the reimbursement landscape.